US-based Acelity has signed an agreement to buy British advanced wound care firm Crawford Healthcare and its assets.

The transaction covers Crawford’s commercial products, research and development (R&D) capabilities and manufacturing operations in Cheshire, UK.

However, financial details of the acquisition have not been disclosed.

The move is intended to expand Acelity’s advanced wound dressings (AWD) portfolio and bolster its footprint in the advanced wound healing market.

Currently, Acelity’s AWD portfolio includes Promogran Prisma Matrix collagen dressing, Tielle Dressing Family and Adaptic Dressings.

“Let Bionic Pancreas will ultimately allow people to choose between multiple CGMs, multiple insulin types, and to choose glucagon.”

Acelity president and CEO Andrew Eckert said: “This transaction solidifies our ability to offer the most comprehensive line of wound care solutions and will enable us to create and consolidate leading positions in high-growth market segments; expand and strengthen our customer relationships; and enhance our innovation expertise for the benefit of clinicians and patients around the world.”

Crawford develops and commercialises treatments for skin care and repair. Its portfolio consists of KerraMax Care foam line, and KerraFoam and KerraCel antimicrobial gelling fibre brands for AWD.

The combination of the companies’ respective wound dressing products with Acelity’s negative pressure wound therapy platforms is intended to create a broad portfolio for global wound care.

Crawford Healthcare chief executive Richard Anderson said: “Becoming part of the world’s largest wound care company will provide us with the scale to optimise our potential within the US, the largest global market and the ability to further access and grow in other international markets with our best-in-class advanced wound care products.”